Purpose Neuroendocrine tumours (NET) are uncommon and may be localized in many
different places in the body. Traditional imaging has mainly been performed with CT and …

Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

Abstract Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) and
positron emission tomography/computed tomography (PET/CT) are valuable diagnostic …

In patients with neuroendocrine tumours (NETs), a combination of morphological imaging
and nuclear medicine techniques is mandatory for primary tumour visualization, staging and …

Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Neuroendocrine tumors (NETs) are tumors originated from neuroendocrine cells in the body.
The localization and the detection of the extent of NETs are important for diagnosis and …

Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …

Neuroendocrine tumors (NETs) are rare neoplasms characterized by overexpression of
somatostatin receptors (SSTRs). Functional imaging plays a crucial role in management of …

Objective (s): In view of somatostatin receptor (SSR) expression on cell membranes of the
majority of neuroendocrine tumors (NETs), functional imaging exploiting analogs of SSR …